PassPort Technologies

Executive Summary

PassPort Technologies is a private biotech company based in San Diego, developing a novel active transdermal drug delivery platform called PassPort®. The system uses microporation technology to enable the delivery of a wide range of therapeutics and vaccines through the skin, potentially improving patient compliance and outcomes for biologics and small molecules. Founded in 2016, the company is advancing an internal pipeline of off-patent drugs while also engaging in collaborations with pharmaceutical partners to leverage its technology for their proprietary compounds. As a pre-clinical stage company, PassPort has not yet disclosed specific financial details or lead program timelines, but its platform approach offers versatility across multiple indications. The company's strategy centers on creating value through its innovative delivery system, which could differentiate it in the crowded drug delivery space. However, given its early stage, significant risks remain regarding clinical validation, regulatory clearance, and commercial adoption. The management team and scientific advisors are not publicly detailed, but the company operates in the competitive San Diego biotech hub. Near-term focus is expected on advancing its lead candidate(s) into human testing and expanding partnerships to demonstrate broad applicability.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 1 clinical trial for lead candidate40% success
• Q4 2026Announcement of new pharmaceutical partnership60% success
• Q1 2027Publication of preclinical data in peer-reviewed journal70% success